Oxalic Acid

Oxalic Acid

SCHEMBL6922334

COc1ccc(NC(=O)c2ccc(-c3ccc(-c4noc(C)n4)cc3C)cc2)cc1CCCN(C)C.O=C(O)C(=O)O

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRM1SLC6A4

The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 known ✓ P31645 3/20 0.72
HTR1D P28221 12/20 0.95
HTR1B P28222 10/20 0.95
HTR2A P28223 9/20 0.95
MEN1 O00255 3/20 0.73
MAPT P10636 3/20 0.73
KMT2A Q03164 3/20 0.73
TDP1 Q9NUW8 3/20 0.73
TP53 P04637 2/20 0.73
CYP3A4 P08684 2/20 0.73
CYP2D6 P10635 2/20 0.73
MAPK1 P28482 2/20 0.73
HSD17B10 Q99714 2/20 0.73
HPGD P15428 2/20 0.73
KDM4E B2RXH2 1/20 0.73
ALDH1A1 P00352 1/20 0.73
CYP1A2 P05177 1/20 0.73
ALOX15 P16050 1/20 0.73
HTR2C P28335 2/20 0.72
CHRM2 P08172 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7403529 0.98 HTR1D (1.00) HTR1DHTR1BHTR2AMEN1MAPT
SCHEMBL6487806 0.93 HTR1D (0.91) HTR1DHTR1BHTR2AMEN1MAPT
SCHEMBL7444950 0.88 HTR1D (0.82) HTR1DHTR1BHTR2AMEN1MAPT
SCHEMBL6924931 0.87 HTR1D (0.92) HTR1DHTR1BHTR2AMEN1MAPT
Oxalic Acid SCHEMBL8687910 0.86 HTR1D (0.95) HTR1DHTR1BHTR2AMEN1MAPT
SCHEMBL29390887 0.84 HTR1D (1.00) HTR1DHTR1BHTR2AMEN1MAPT
SCHEMBL2360553 0.84 HTR1D (1.00) HTR1DHTR1BHTR2AMEN1MAPT
SCHEMBL8687667 0.84 HTR1D (0.77) HTR1DHTR1BHTR2AMEN1MAPT
Hydrochloric Acid SCHEMBL25382964 0.83 HTR1D (1.00) HTR1DHTR1BHTR2AMEN1MAPT
SCHEMBL8692598 0.83 HTR1D (1.00) HTR1DHTR1BHTR2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1001766-B1 COMPOUNDS FOR THE TREATMENT OF CCR5-MEDIATED DISEASES SMITHKLINE BEECHAM CORP (US) 2003-04-09 EP claimed
US-6515027-B1 Ligands, agonists or antagonists, of the CC chemokine receptor CC-CKR5 SMITHKLINE BEECHAM CORP. 2003-02-04 US claimed
JP-2002511879-A 2002-04-16 JP claimed
EP-1001766-A4 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORP (US) 2001-04-04 EP claimed
EP-1001766-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2000-05-24 EP claimed
WO-1999001127-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 1999-01-14 WO claimed
EP-4143235-A1 METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION IncellDx, Inc. (US) 2023-03-08 EP disclosed
WO-2021222069-A1 METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION INCELLDX, INC. (US) 2021-11-04 WO disclosed
EP-1001766-B1 COMPOUNDS FOR THE TREATMENT OF CCR5-MEDIATED DISEASES SMITHKLINE BEECHAM CORP (US) 2003-04-09 EP disclosed
US-6515027-B1 Ligands, agonists or antagonists, of the CC chemokine receptor CC-CKR5 SMITHKLINE BEECHAM CORP. 2003-02-04 US disclosed